Loading organizations...
Lurie Investments operates as an investment firm focused on venture capital and private equity within the biomedical community. It strategically backs companies developing innovative solutions in medical devices, therapeutics, diagnostics, nanotechnology, and MEMS technology. The firm provides capital and strategic support, fostering advancements across these specialized fields.
The firm functions as the venture capital arm of the Ann and Robert H. Lurie Foundation, leveraging an established financial legacy. This structure enables Lurie Investments to identify and nurture early-stage and growth-oriented companies. Adam Lurie, a managing partner, contributes to the firm's strategic direction, with active involvement across its portfolio, including artificial intelligence interests.
Lurie Investments targets companies pioneering advancements in healthcare and technology, partnering with innovators. Its vision centers on fostering scientific and technological progress within the biomedical landscape. The firm identifies and scales businesses that address critical needs, driving significant impact through strategic investments and pushing innovation boundaries.
Lurie Investments has 4 tracked investments across 2 companies. The latest tracked deal is $60.0M Series D in Viamet Pharmaceuticals in October 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2014 | Viamet Pharmaceuticals | $60.0M Series D | Adrian Howd, Woodford Investment Management | Hatteras Venture Partners, Astellas Venture Management, Intersouth Partners, Lilly Ventures, Novartis |
| Jan 4, 2012 | CytoPherx | $34.0M Other Equity | Capital Midwest Fund, Michael Bunker, Leslie Bottorff | Aphelion Capital, Apjohn Ventures, Charter OAK Equity, Dow/Union Carbide Employee Pension Plans, Emergent Medical Partners, Kaiser Permanente Ventures, North Coast Technology Investors |
| Jan 1, 2012 | CytoPherx | $34.0M Series C | Capital Midwest Fund, Early Stage Partners, ONSET Ventures | GE Ventures, Aphelion Capital, Apjohn Ventures, Charter OAK Equity, Dow/Union Carbide Employee Pension Plans, Emergent Medical Partners, Kaiser Permanente Ventures, North Coast Technology Investors |
| Jun 18, 2010 | CytoPherx | $5.0M Series B | Diamond Capital Management | Apjohn Ventures |